Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
Mazurek M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Paquette M, Zint K, França LR, Lu S, Bartels DB, Huisman MV, Lip GYH; GLORIA-AF Investigators.
Mazurek M, et al. Among authors: teutsch c.
Am Heart J. 2019 Dec;218:123-127. doi: 10.1016/j.ahj.2019.08.012.
Am Heart J. 2019.
PMID: 31806087
GLORIA-AF is a large, ongoing, prospective, global registry program run in 3 phases, assessing long-term safety and effectiveness of dabigatran etexilate (dabigatran) in patients with newly diagnosed atrial fibrillation (AF) in clinical practice. ...
GLORIA-AF is a large, ongoing, prospective, global registry program run in 3 phases, assessing long-term safety and effectiveness of …